CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 4.67: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.12%Above 5Y avg (0.69%)
Annual Rate
CNY 0.25Paid annual
Payout Ratio
42.2%Sustainable
Payback Period
86.4 yr
Last Ex-Dividend
Jul 22, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.10BCNY459.79M · vs all stocks (USD)
Trailing P/E
36.22xRevenue (TTM)
1.11BCNY165.09M · vs all stocks (USD)
Profit Margin
7.80%Beta
-0.2720xvs all stocks
52-Week Change
-6.53%vs all stocks
Market Capitalization
3.10BCNY459.79M · vs all stocks (USD)
Enterprise Value
2.05BCNY303.68M · vs all stocks (USD)
Trailing P/E
36.22xPrice to Sales (TTM)
2.85xPrice to Book (MRQ)
1.83xEnterprise to Revenue
1.84xEnterprise to EBITDA
16.47xGross Margin
54.85%Profit Margin
7.80%Operating Margin
13.38%Return on Assets (TTM)
2.29%Return on Equity (TTM)
5.13%Revenue (TTM)
1.11BCNY165.09M · vs all stocks (USD)
Revenue per Share (TTM)
8.19CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-11.10%Gross Profit (TTM)
578.81MCNY85.84M · vs all stocks (USD)
EBITDA (TTM)
135.91MCNY20.16M · vs all stocks (USD)
Net Income (TTM)
86.79MCNY12.87M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-30.40%Operating Cash Flow (TTM)
130.05MCNY19.29M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
68.37MCNY10.14M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2500CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
1.12%vs all stocks
5-Year Average Dividend Yield
0.69%vs all stocks
Payout Ratio
42.17%Minority Interest (Equity)
2.20MCNYFY2025 · Dec 31, 2025Revenue
1.14BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
549.08MCNYFY2025 · Dec 31, 2025Gross Profit
591.79MCNYFY2025 · Dec 31, 2025Operating Income
122.28MCNY18.13M · vs all stocks (USD)
Pre-tax Income
108.95MCNYFY2025 · Dec 31, 2025Income Tax Expense
12.93MCNYFY2025 · Dec 31, 2025Net Income
96.02MCNYFY2025 · Dec 31, 2025EBIT
111.14MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
172.28MCNYFY2025 · Dec 31, 2025Research & Development
53.11MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
334.71MCNYFY2025 · Dec 31, 2025Other Operating Expenses
12.29MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
14.55MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.18MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.9200CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.9200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
104.65MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
104.65MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
96.02MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
257.86KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-42.37MCNYFY2025 · Dec 31, 2025Free Cash Flow
-84.50MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.09BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
96.02MCNYFY2025 · Dec 31, 2025Other Non-cash Items
2.74MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-121.29MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-19.85MCNYFY2025 · Dec 31, 2025Capital Expenditures
-42.12MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-42.12MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
50.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-101.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-43.89MCNYFY2025 · Dec 31, 2025Other Financing Charges
-478.47KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-95.37MCNYFY2025 · Dec 31, 2025Shares Outstanding
138.17MSharesUpdated Aug 19, 2026Float Shares
82.66MSharesUpdated Aug 19, 2026% Held by Insiders
39.33%vs all stocks
% Held by Institutions
3.26%vs all stocks
Total Cash (MRQ)
1.23BCNY182.43M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.13CNYUpdated Aug 19, 2026Total Debt (MRQ)
152.35MCNY22.59M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0891xCurrent Ratio (MRQ)
3.76xBook Value per Share (MRQ)
12.68CNYUpdated Aug 19, 2026Total Assets
2.32BCNY344.47M · vs all stocks (USD)
Total Current Assets
1.80BCNYFY2025 · Dec 31, 2025Total Liabilities
633.75MCNYFY2025 · Dec 31, 2025Total Non-current Assets
520.01MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
109.60MCNYFY2025 · Dec 31, 2025Total Current Liabilities
524.15MCNYFY2025 · Dec 31, 2025Cash
1.09BCNYFY2025 · Dec 31, 2025Cash Equivalents
65.78KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.09BCNYFY2025 · Dec 31, 2025Accounts Receivable
423.39MCNYFY2025 · Dec 31, 2025Inventory
110.82MCNYFY2025 · Dec 31, 2025Accounts Payable
127.57MCNYFY2025 · Dec 31, 2025Short-term Debt
98.88MCNYFY2025 · Dec 31, 2025Other Current Liabilities
523.51KCNYFY2025 · Dec 31, 2025Long-term Debt
1.95MCNYFY2025 · Dec 31, 2025Common Stock (Book)
106.28MCNYFY2025 · Dec 31, 2025Retained Earnings
703.10MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.69BCNY250.48M · vs all stocks (USD)
Treasury Stock
25.08MCNYFY2025 · Dec 31, 202552-Week Low
19.00CNYUpdated Aug 19, 202652-Week High
32.98CNYUpdated Aug 19, 202652-Week Change
-6.53%vs all stocks
Beta
-0.2720xvs all stocks
50-Day MA
21.39CNYUpdated Aug 19, 2026200-Day MA
24.59CNYUpdated Aug 19, 2026Avg 10-Day Volume
3.82MSharesUpdated Aug 19, 2026Avg 30-Day Volume
5.38MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.6400CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.55Profit Margin: 0.08
Financial Health
Altman Z-Score 4.67: safe zoneNotable
Altman Z-Score: 4.67
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Anhui Fengyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ocugen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong VTR Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlow
Guanhao Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cabaletta Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Kawin Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Yibai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Medlander Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking